InMed Pharmaceuticals(INM.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
InMed Pharmaceuticals
INM.US
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
4.623 T
INM.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking107/190
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-112.65%E
    • Profit Margin-172.17%E
    • Gross Margin0.00%E
  • Growth ScoreB
    • Revenue YoY285.22%A
    • Net Profit YoY-2.39%C
    • Total Assets YoY-1.57%D
    • Net Assets YoY-1.85%D
  • Cash ScoreB
    • Cash Flow Margin87.63%C
    • OCF YoY285.22%A
  • Operating ScoreC
    • Turnover0.54C
  • Debt ScoreB
    • Gearing Ratio24.55%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    InMed Pharmaceuticals agrees to all-stock merger with Mentari Therapeutics

    PUBT·
    US
    INM
    +140.93%
    US
    IHE
    +0.79%
    PUBT·
    US
    INM
    +140.93%
    US
    IHE
    +0.79%

    InMed Pharmaceuticals Amends Preferred Investment Options | INM Stock News

    StockTitan·
    US
    INM
    +140.93%
    US
    BBH
    +0.45%
    US
    ARKG
    -0.71%
    StockTitan·
    US
    INM
    +140.93%
    US
    BBH
    +0.45%
    US
    ARKG
    -0.71%

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    benzinga_article·
    US
    INM
    +140.93%
    US
    AMLX
    -2.02%
    US
    SRTS
    -2.59%
    benzinga_article·
    US
    INM
    +140.93%
    US
    AMLX
    -2.02%
    US
    SRTS
    -2.59%

    InMed Reports Q3 FY2026: Net Loss $3.0M, Cash $5.2M, INM-901 shows human organoid anti‑inflammatory effects

    TradingView·
    US
    INM
    +140.93%
    US
    BBH
    +0.45%
    US
    FBT
    +0.48%
    TradingView·
    US
    INM
    +140.93%
    US
    BBH
    +0.45%
    US
    FBT
    +0.48%
    © 2026 Longbridge｜Disclaimer